Nivolumab

Generic Name
Nivolumab
Brand Names
Opdivo, Opdualag
Drug Type
Biotech
Chemical Formula
-
CAS Number
946414-94-4
Unique Ingredient Identifier
31YO63LBSN
Background

Nivolumab is a fully human IgG4 antibody targeting the immune checkpoint programmed death receptor-1 (PD-1). This antibody was produced entirely in mice and grafted onto human kappa and IgG4 Fc region with the mutation S228P for additional stability and reduced variability. It was developed by Bristol Myers Squibb.
...

Indication

Nivolumab is indicated to treat unresectable or metastatic melanoma, melanoma as adjuvant treatment, resectable or metastatic non-small cell lung cancer, small cell lung cancer, advanced renal cell carcinoma, classical Hodgkin lymphoma, squamous cell carcinoma of the head and neck, urothelial carcinoma, microsatellite instability-high or mismatch repair defi...

Associated Conditions
Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma, Advanced Gastric Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Advanced Renal Cell Carcinoma, Classical Hodgkin's Lymphoma, Completely resected Stage IIB melanoma, Completely resected Stage III melanoma, Completely resected Stage IV melanoma, Hepatocellular Carcinoma, Locally Advanced Hepatocellular Carcinoma, Locally Advanced Non-Small Cell Lung Cancer, Melanoma, Metastatic Colorectal Cancer (CRC), Metastatic Esophageal Adenocarcinoma, Metastatic Esophageal Squamous Cell Carcinoma, Metastatic Gastric Adenocarcinoma, Metastatic Gastric Cancers, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Hepatocellular Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Metastatic Renal Cell Carcinoma ( mRCC), Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC), Metastatic Urothelial Carcinoma (UC), Mismatch Repair-deficient (dMMR) Metastatic Colorectal Cancer (CRC), Muscle-invasive Urothelial Carcinoma, Poor Risk Advanced Renal Cell Cancer, Recurrent Non-small Cell Lung Cancer, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma, Relapsed or Refractory Classical Hodgkin's Lymphoma, Resectable Non-small Cell Lung Cancer, Stage IIB Melanoma, Stage IIC Melanoma, Unresectable Esophageal Squamous Cell Carcinoma, Unresectable Locally Advanced Urothelial Cancer, Unresectable Melanoma, Urothelial Carcinoma, Completely resected Stage IIC melanoma, Intermediate risk Advanced Renal Cell Cancer, Locally advanced Urothelial Carcinoma, Metastatic Microsatellite Instability High Colorectal Cancer, Metastatic Mismatch Repair Deficient Colorectal Cancer, Metastatic gastroesphageal juntion adenocarcinoma, Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN), Relapsed Classical Hodgkin's Lymphoma, Residual Esophageal Cancer, Residual Gastroesophageal Junction Cancer, Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma, Unresectable, advanced Esophageal Squamous Cell Carcinoma (ESCC), Unresectable, metastatic Esophageal Squamous Cell Carcinoma (ESCC), Unresectable, recurrent Esophageal Squamous Cell Carcinoma (ESCC)
Associated Therapies
Complete Surgical Resection, Neoadjuvant Therapies
Clinical Trials
Related News

Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin Lymphoma

First Posted Date
2024-12-20
Last Posted Date
2024-12-20
Lead Sponsor
University of Washington
Target Recruit Count
125
Registration Number
NCT06745076
Locations
🇺🇸

Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Phase 3 Clinical Trial Of ANKTIVA Plus NIVOLUMAB And DOCETAXEL Versus DOCETAXEL Monotherapy In Participants With Advanced Or Metastatic Non-Small Cell Lung Cancer

Phase 3
Not yet recruiting
Conditions
NSCLC, Stage III
Interventions
Drug: ANKTIVA
Drug: Nivolumab
Drug: Docetaxel
First Posted Date
2024-12-20
Last Posted Date
2024-12-20
Lead Sponsor
ImmunityBio, Inc.
Target Recruit Count
460
Registration Number
NCT06745908

SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

First Posted Date
2024-12-19
Last Posted Date
2024-12-19
Lead Sponsor
Immatics US, Inc.
Target Recruit Count
360
Registration Number
NCT06743126

Clinical Outcomes of Patients With Resectable Non-Small Cell Lung Cancer Receiving Neoadjuvant Nivolumab Plus Chemotherapy in France

First Posted Date
2024-12-16
Last Posted Date
2024-12-16
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
101
Registration Number
NCT06735781
Locations
🇫🇷

Centre François Baclesse, Caen, France

🇫🇷

Centre Léon Bérard, Lyon, France

🇫🇷

Hospices Civils de Lyon, Lyon, France

and more 4 locations

Diclofenac for the Treatment of Patients with Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy

First Posted Date
2024-12-12
Last Posted Date
2024-12-12
Lead Sponsor
Emory University
Target Recruit Count
20
Registration Number
NCT06731270
Locations
🇺🇸

Emory University Hospital Midtown, Atlanta, Georgia, United States

🇺🇸

Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States

Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS

First Posted Date
2024-11-18
Last Posted Date
2024-11-18
Lead Sponsor
Peking University Shenzhen Hospital
Target Recruit Count
200
Registration Number
NCT06692491

Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk Recurrence

First Posted Date
2024-11-12
Last Posted Date
2024-11-21
Lead Sponsor
University of California, Irvine
Target Recruit Count
23
Registration Number
NCT06682728
Locations
🇺🇸

Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, California, United States

Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY)

Phase 1
Not yet recruiting
Conditions
Melanoma
Interventions
Drug: Nivolumab
Drug: Relatlimab
Drug: Ipilimumab
First Posted Date
2024-11-11
Last Posted Date
2024-11-11
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
30
Registration Number
NCT06683755
Locations
🇺🇸

The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States

Agnostic Therapy in Rare Solid Tumors

First Posted Date
2024-10-15
Last Posted Date
2024-10-15
Lead Sponsor
Instituto do Cancer do Estado de São Paulo
Target Recruit Count
28
Registration Number
NCT06638931
Locations
🇧🇷

Hospital São Rafael, Salvador, Bahia, Brazil

🇧🇷

Hospital São Carlos, Fortaleza, Ceará, Brazil

🇧🇷

Hospital Santa Cruz, Curitiba, Paraná, Brazil

and more 5 locations

PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma

First Posted Date
2024-10-14
Last Posted Date
2024-10-14
Lead Sponsor
Washington University School of Medicine
Target Recruit Count
68
Registration Number
NCT06639607
Locations
🇺🇸

Washington University School of Medicine, Saint Louis, Missouri, United States

🇺🇸

Duke University Medical Center, Durham, North Carolina, United States

🇺🇸

MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy